Kazia Therapeutics

Kazia Therapeutics KZIA Stock

$5.49   3.389830%
Add to favorites
Market Cap
$85.36M
LOW - HIGH [24H]
$5.25 - $5.75
VOLUME [24H]
$226.31K
P/E Ratio
0
Earnings per share
-$6.85
ISIN
US48669G3039
Price   Prediction

Kazia Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Kazia Therapeutics (KZIA) stock price today is 5.49 USD on Tech Market Small (+3.39% on the day). Updated .

Kazia Therapeutics KZIA Financial and Trading Overview

Kazia Therapeutics stock price 5.49 USD
Previous Close 5.31 USD
Open 5.25 USD
Bid 7.4 USD x 500
Ask 5.82 USD x 100
Day's Range 5.25 - 5.75 USD
52 Week Range 4.86 - 17.4 USD
Volume 141.17K USD
Avg. Volume 294K USD
Market Cap 84.9M USD
Beta (5Y Monthly) 2.356
PE Ratio (TTM) N/A
EPS (TTM) -6.85 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 28.24 USD

KZIA Valuation Measures

Enterprise Value -9167061 USD
Trailing P/E N/A
Forward P/E -577.54126
PEG Ratio (5 yr expected) 1.01
Price/Sales (ttm) 44.714783
Price/Book (mrq) 1.8950791
Enterprise Value/Revenue -4.828
Enterprise Value/EBITDA 0.514

Trading Information

Kazia Therapeutics Stock Price History

Beta (5Y Monthly) 2.356
52-Week Change -31.39%
S&P500 52-Week Change 10.51%
52 Week High 17.4 USD
52 Week Low 4.86 USD
50-Day Moving Average 8.71 USD
200-Day Moving Average 10.56 USD

KZIA Share Statistics

Avg. Volume (3 month) 294K USD
Avg. Daily Volume (10-Days) 357.07K USD
Shares Outstanding 15.55M
Float 9.39M
Short Ratio 6.71
% Held by Insiders 15.41%
% Held by Institutions 45.98%
Shares Short 1.45M
Short % of Float 9.30%
Short % of Shares Outstanding 9.28%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:5

Financial Highlights

Fiscal Year

Fiscal Year Ends June 30, 2025
Most Recent Quarter (mrq) December 31, 2025
Next Fiscal Year End June 30, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -964.21%
Gross Margin 100.00%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -25.70%
Return on Equity (ttm) -106.89%

Income Statement

Revenue (ttm) 1.9M USD
Revenue Per Share (ttm) 0.85 USD
Quarterly Revenue Growth (yoy) 312.40%
Gross Profit (ttm) 1.9M USD
EBITDA -17840660 USD
Net Income Avi to Common (ttm) -22800680 USD
Diluted EPS (ttm) -6.85
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 69.46M USD
Total Cash Per Share (mrq) 6.13 USD
Total Debt (mrq) 98.81K USD
Total Debt/Equity (mrq) 0.21 USD
Current Ratio (mrq) 2.871
Book Value Per Share (mrq) 2.8811462

Cash Flow Statement

Operating Cash Flow (ttm) -14398379 USD
Levered Free Cash Flow (ttm) 1.1M USD

Profile of Kazia Therapeutics

Country United States
State NSW
City Sydney
Address Three International Towers
ZIP 2000
Phone 61 2 9472 4101
Website https://www.kaziatx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 6

Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group; as well as licence agreement with Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Q&A For Kazia Therapeutics Stock

What is a current KZIA stock price?

Kazia Therapeutics KZIA stock price today per share is 5.49 USD.

How to purchase Kazia Therapeutics stock?

You can buy KZIA shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kazia Therapeutics?

The stock symbol or ticker of Kazia Therapeutics is KZIA.

Which industry does the Kazia Therapeutics company belong to?

The Kazia Therapeutics industry is Biotechnology.

How many shares does Kazia Therapeutics have in circulation?

The max supply of Kazia Therapeutics shares is 15.55M.

What is Kazia Therapeutics Price to Earnings Ratio (PE Ratio)?

Kazia Therapeutics PE Ratio is now.

What was Kazia Therapeutics earnings per share over the trailing 12 months (TTM)?

Kazia Therapeutics EPS is -6.85 USD over the trailing 12 months.

Which sector does the Kazia Therapeutics company belong to?

The Kazia Therapeutics sector is Healthcare.

Kazia Therapeutics KZIA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24866.3 USD —
+1.79
1.44B USD — 24775.7 USD — 24930.78 USD — — 1.44B USD —
us US Tech Capital Market Composite RCMP US 109.73 USD —
+0.87
— — 109.6 USD — 110.3 USD — — — —
us US Tech Health Care IXHC US 1317.9 USD —
-0.49
— — 1317.71 USD — 1333.62 USD — — — —
$2.2T
Total marketcap
$72.57B
Total volume
BTC 58.16%   •   ETH 9.99%
Dominance
Select currency